The Journal of Advances in Leukemia (JAL) serves as a premier platform for disseminating cutting-edge research in leukemia science, bridging fundamental discovery with clinical translation. As a peer-reviewed, open access journal, JAL provides immediate global visibility to high-quality investigations that advance our understanding of leukemia pathogenesis, diagnosis, treatment, and outcomes.
JAL welcomes contributions from basic scientists, clinical researchers, hematologists, oncologists, and healthcare professionals worldwide. Our commitment to rigorous peer review, rapid publication, and unrestricted access ensures that breakthrough findings reach the broadest possible audience without delay, accelerating progress against these devastating blood cancers.
Our Mission
To advance the scientific understanding and clinical management of leukemia by publishing innovative, methodologically sound research that transforms patient care and outcomes.
We are dedicated to fostering a collaborative international community where researchers share discoveries that illuminate disease mechanisms, refine diagnostic approaches, optimize therapeutic strategies, and improve quality of life for patients worldwide.
Core Values
Scientific Excellence
Rigorous methodology, reproducible results, and meaningful contributions to leukemia knowledge.
Transparent Process
Fair, constructive peer review with clear ethical standards and author support.
Global Accessibility
Open access publishing removes barriers, democratizing knowledge for all stakeholders.
Research Scope
JAL publishes multidisciplinary research spanning the full spectrum of leukemia science and clinical care
Disease Biology & Mechanisms
- Molecular pathogenesis of acute and chronic leukemias
- Genetic and epigenetic alterations
- Signal transduction pathways
- Leukemic stem cell biology
- Microenvironment interactions
Diagnostics & Classification
- Novel biomarker discovery and validation
- Advanced cytogenetic techniques
- Molecular diagnostic methods
- Risk stratification systems
- Minimal residual disease detection
Therapeutic Advances
- Targeted therapy development
- Immunotherapy approaches
- Chemotherapy optimization
- Stem cell transplantation
- Drug resistance mechanisms
Clinical Outcomes & Care
- Clinical trial results
- Treatment protocols and guidelines
- Survivorship and quality of life
- Supportive care strategies
- Health services research
Pediatric Leukemia
- Age-specific disease characteristics
- Childhood leukemia subtypes
- Developmental considerations
- Long-term survivor outcomes
- Family-centered care approaches
Emerging Technologies
- Next-generation sequencing applications
- Single-cell analysis techniques
- Artificial intelligence in diagnosis
- Novel drug delivery systems
- Precision medicine platforms
Article Types We Welcome
Expert Editorial Leadership
JAL is guided by an international editorial board comprising distinguished hematologists, oncologists, molecular biologists, and clinical researchers with expertise across all leukemia subtypes. Our editors are committed to maintaining the highest standards of scientific integrity while providing constructive guidance to authors.
This collaborative approach ensures thorough, fair peer review that strengthens manuscripts and advances the field. Our editorial team works diligently to provide timely decisions and support authors throughout the publication process.
Meet Our Editorial BoardOur Commitment to Authors
Rapid Review
Efficient peer review process with timely decisions and constructive feedback to move science forward faster.
Open Access
Immediate, unrestricted access to published articles ensures maximum visibility and impact for your research.
Author Support
Dedicated editorial assistance from submission through publication, ensuring a smooth publishing experience.
Ethical Standards
Strict adherence to publication ethics guidelines, protecting research integrity and author rights throughout.
Why Publish With JAL?
Global Reach: Open access publishing ensures your research reaches clinicians, researchers, and patients worldwide without subscription barriers, maximizing your contribution's impact on leukemia care.
Multidisciplinary Audience: JAL attracts readers from basic science, translational research, and clinical practice, facilitating cross-disciplinary dialogue that accelerates bench-to-bedside innovation.
Rigorous Standards: Expert peer review maintains scientific quality while constructive feedback strengthens your manuscript, enhancing its contribution to the field.
Rapid Publication: Streamlined editorial workflows and efficient production processes ensure your findings are disseminated quickly, keeping pace with the rapidly evolving leukemia landscape.
Join the Global Community Advancing Leukemia Research
